BrainStorm Cell Therapeutics announced a net loss of $2.1 million for Q1 2026 while progressing with preparations for its Phase 3b ENDURANCE trial of NurOwn, a stem cell therapy for ALS. The trial aims to enroll about 200 patients to test NurOwn's effectiveness in early-stage ALS. The company secured $2.2 million in recent private placements to support operations and trial readiness. Successful trial completion could lead to a new Biologics License Application for NurOwn, addressing a critical need for ALS treatments.
Winnebago Industries announced a quarterly cash dividend of $0.35 per share, payable on June 24, 2026, to shareholders of record as of June 10, 2026. This dividend marks the company's 48th consecutive quarterly payment, reflecting confidence in its b...
DOOR (formerly Latch, Inc.) reported its Q1 2026 financial results showing a 19.1% increase in software revenue to $6.1 million, driven by subscription growth. Total revenue remained flat at $15.7 million as gains in software and hardware offset a de...
Extra Space Storage Inc. announced a second quarter 2026 dividend of $1.62 per share, payable on June 30, 2026, to shareholders of record as of June 15, 2026. The company is a leading self-storage real estate investment trust in the U.S., operating o...
Covenant Logistics Group announced a quarterly cash dividend of $0.07 per share for both Class A and Class B common stock. The dividend will be paid to shareholders of record as of June 5, 2026, with payment expected on June 26, 2026. This dividend d...
Marpai, Inc. announced its Q1 2026 financial results, highlighting near completion of its IT and claims processing migration to a unified cloud platform expected to reduce costs and improve service from Q2 2026. Despite a slight revenue decline to $4...
